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1. Introduction 
Infection by human papilloma virus (HPV) attracted attention in connection with cervical 
cancer in humans (zur Hausen, 1996). HPV type 16 alone accounts for approximately 50% of 
all cases of cervical cancer. The virus icosahedral capsid is composed of the L1 major and the 
L2 minor proteins. L1 alone has the capacity to self-assemble into virus-like particles (VLPs) 
without participation of L2 or other proteins. Because of similar immunogenicity compared to 
infectious virions, VLPs can be produced and used as a safe prophylactic vaccine against viral 
transmission of cervical cancer. During recent years two highly efficient VLP-based HPV 
vaccines (e.g. Gardasil, Merck MSD and Cervarix, GlaxoSmithKline) become available. For 
commercial production of vaccines and recombinant therapeutics, plants are often considered 
as a cost-effective alternative with several benefits. Firstly, production in plants can be easily 
scaled up in the case of acute demand for production and secondly, produced proteins are 
unlikely to be contaminated by human or animal pathogens, toxins and oncogenic sequences. 
Moreover, plants provide a convenient environment for protein expression and storage 
including the possibility of direct administration as edible vaccine if expressed in the 
appropriate plant tissue. In this article, we report recent promising advances in the production 
of prophylactic and therapeutic vaccines against HPV by expression of the relevant antigens in 
plants, and discuss future prospects for the use of such vaccines. 
2. HPV vaccines 
2.1 Structure of HPV capsid and neutralizing epitopes on its surface 
Papilloma viruses (PVs) are small tissue specific double-stranded DNA tumor viruses, 
classified in the taxonomic family of Papillomaviridae. The Human Papilloma Viruses (HPVs) 
are phylogenetically closely related with similar biological properties among each other and 
with animal papillomaviruses that are host-specific to other vertebrates including amphibians, 
reptiles, birds and a variety of land and sea mammals. Animal PVs have been studied either as 
disease carrier and transmitters in animals or as models of human PV infection (Brandsma et 
al.; 1994; Campo 1997). Due to etiological connection with the high-rate mortality cervical 
cancer, the main attention is concentrated on the genital high-risk HPV types 16, 18, 33 and 58 
as the leading cause of cancer (Munoz et al., 2003). The low-risk types 6 and 11 are associated 
with benign epithelial papillomas or warts that occur in 5–12% of normal women (Heim et al, 
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1995), however, HPV6 and 11 are the most commonly diagnosed to coinfect and comorbid in 
immunosuppressed individuals with malignant HPVs (Jay & Moscicki, 2000). 
Papillomavirus infection induces type-specific immune response, directed mainly against the 
major capsid protein L1, rather than L2 minor protein, which also participates in the formation 
of the shell of native HPV particles. The viral capsid is primarily composed of 360 copies of L1 
protein organized into 72 L1-pentamers (capsomeres) and associated with 12 or more copies of 
the minor L2 protein. When expressed in various recombinant system, L1 readily self-
assembles, even in the absence of L2, into noninfectious virus-like particles (VLPs). VLPs are 
also organized into 72 capsomeres of L1 protein (Fig. 1C) and are immunologically 
indistinguishable from the native virions (Fig. 1B). The 504-residue of the L1 protein chain 
contains 12 ǐ-strands, 6 loops, and 5 Ǐ-helices that form “jelly roll” ǐ-sandwich (Fig. 1D).  
 
Fig. 1. Structure of the HPV capsid. (A) Small (T=1) VLPs derived from HPV-L1; (B) Full-
size (T=7) Papillomavirus particles; (C) HPV16 capsomere (L1-pentamer) in the 
conformation found in small VLPs (Chen et al., 2000). Three subunits are shown in green, 
blue and red. The C’-terminal arms are in gray, to indicate that these portions of the subunit 
rearrange when L1-pentamers assemble into virions or into full-sized capsids; (D) The 3D 
structure of human papillomavirus 16 L1 monomer (HPV16L1). Secondary structural 
elements are labeled, with letters B–J for ǐ-strands and h1–h5 for the 5 Ǐ-helices. Loops 
between strands are labeled B–C, C–D, etc. The first and the last residues are marked N (20) 
and C (474), respectively. The two cysteines that participate in the interpentamer disulphide 
bonding within the virion or in the virion-sized particles are shown in yellow, together with 
their residue numbers, 175 and 428. (Modis et al., 2002) 
Some residues in the L1 protein, such as Asp202, Cys175, and Cys428 of HPV16 L1, are very 
important for VLP formation  (Slupetzky et al., 2001), however some residues at the C’-
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terminus can be truncated and replaced with heterologous epitopes or short polypeptides up 
to 60 amino acids without disrupting the assembly of VLPs (Paintsil et al., 1996; Müller et al., 
1997; Paz De la Rosa et al., 2009). These chimeric VLPs (cVLPs) can induce strong immune 
responses against not only the inserted epitopes or polypeptides, but also the VLP shell 
(Freyschmidt et al., 2004; Varsani et al., 2003a; Xu et al., 2006). Experiments in vitro showed that 
a short N’-terminal segment of the L1 polypeptide chain acts as a switch between T=7 (72 L1-
pentamer) and T=1 (12 L1-pentamer) VLP assembly (Fig. 1B) (Chen et al., 2000). 
Structural analysis has revealed that BC, EF, FG, HI and DE hyper variable loops of L1 (Fig. 
1D) are exposed on the outer surface of the L1-pentamer and form a broad pocket, which 
participate in receptor interaction.  The rim of the pentamer pocket is extremely variable 
contrary to its floor. With a few exceptions, all HPV-neutralizing monoclonal antibodies 
analyzed so far are type-specific and recognize conformational epitopes within these 
surface-exposed hyper variable loops (Pastrana et al., 2004; Fleury et al., 2006). HPV16 and 
HPV11 VLPs epitopes recognized by neutralizing mAbs are shown on Fig. 2 (Roden et al., 
1997a; Ludmerer et al., 1997).  
 
Fig. 2. Surface of the HPV 11 and 16 L1 pentamers. The surface loops are colored differently 
on the surface: BC (orange), DE (violet), EF (yellow), FG (green), and HI (slate). (A) HPV11; 
(B) HPV16. Neutralizing epitopes are schematically indicated on pentamers. Black squares, 
H11.F1 and H11.G5; orange square, H11.H3; red ellipse, H16.V5 and H16.E70. (Bishop et al., 
2007) 
2.2 HPV vaccines of the first generation. The need for second-generation vaccines 
The first applied strategy for HPV prophylactic vaccination aimed on induction of 
neutralizing antibodies against L1 capsid proteins. Currently two vaccines composed of 
HPV-L1 self assembled into VLPs have been developed and are commercially available, a 
Glaxo-Smith Kline bivalent vaccine Cervarix and a Merck, Sharp and Dohme quadrivalent 
vaccine Gardasil (also marketed as Gardisil or Silgard). Bivalent vaccine Cervarix protects 
primarily against HPV 16 and 18 that are produced separately using a recombinant 
Baculovirus expression system. Purified VLPs of each HPV type are formulated with the 
AS04 adjuvant system composed of aluminium hydroxide and 3-O-desacyl-4.-
monophosphoryl lipid A (MPL). Cervarix is stored as a sterile turbid liquid suspension for 
intramuscular injection at 2-8°C with a proposed shelf life 3 years. Gardasil is combination 
of Saccharomyces cerevisce produced HPV 16, 18, 6 and 11 VLPs and has amorphous 
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aluminum hydroxy-phosphate sulfate (AAHS) as an adjuvant. Administrations of vaccine to 
HPV naive women have demonstrated almost complete protection against infection by the 
targeted HPV types. Number of medical trials confirmed the safety of currently used vaccines, 
their efficiency to induce immune response was equal or even higher than that observed 
during a natural infection and to maintain protection for 5 and 7.3 years in the case of Gardasil 
and Cervarix, respectively. (McCormack & Joura, 2010; Schwarz, 2009). The induction of HPV 
neutralizing antibody reaches maximum titers at month 7 after the first vaccination, i.e. 1 
month after administration of the last, third dose. Then the titer decline until month 24 and 
remain stable thereafter (Dillner et al., 2007). Interestingly, the immune response to the 
Gardasil, the tetravalent vaccine, inversely correlates with the age. The induction of 
neutralizing antibody is higher in males and females aged 10 to 15 than in those of an age 
group 16 to 23 year (Villa et al., 2005). For sexually active women in the general population the 
efficiency of vaccination is expected to be much lower. Moreover, total period of protection 
afforded by vaccination is not yet known (Wright et al., 2006). 
Along with the questions who should be vaccinated and at what age the vaccination is the 
most effective (Villa, 2011), issues related to vaccine formulation, production and 
administration have to be also adequately resolved (Schiller & Nardelli-Haefliger, 2006). 
Firstly, multispecific VLPs based vaccines are expensive to manufacture, since they are 
produced in eukaryotic cell culture and extensively purified. Both commercially available 
vaccines require 3 intramuscular injections over a 6 months course to achieve prophylaxis, 
and the direct vaccine cost excluding administration and medical visits is about USD 375 per 
recipient in the United States (Armstrong, 2010), reflecting also costly cold chain handling, 
distribution and storage of a vaccine. More to it, the protection with current vaccines is 
predominately type specific, and so they are not expected to protect against the almost 30% 
of cervical cancers that are HPV16 and 18 independent. Last, but not least, therapeutic 
activity against external genital lesions has not been reported (Villa, 2011). 
Suitable vaccine formulations ensuring VLPs stability in liquid were established for both 
Gardasil (Shank-Retzlaff et al., 2006) and Cervarix (Le Tallec et al., 2009) vaccines. However 
during production fibrous aggregates of VLPs were occasionally observed. This is why 
marketed solutions of concentrated VLPs are protected against aggregation by high 
concentrations of salt. Many other factors including excipients maintaining pH, storage 
stability, temperature and time effectively influence VLPs. For example at high pH and low 
salt concentration, VLPs disassemble into capsomeres with weaker immune response than 
VLPs (Thönes et al., 2008) and denatured L1 protein does not induce any virus neutralizing 
antibody response (Shinje et al., 1991). Stabilization of protein antigens against aggregation 
and degradation in solution is important for antigen purification as well as vaccine 
formulation. Lyophilized VLPs might be an alternative to aqueous droplets for mucosal 
delivery in a powder formulation of a vaccine (Schiller & Nardelli-Haefliger, 2006; Gerber et 
al., 2001). Papillomavirus virions are resistant to desiccation and retain their native 
conformation after freeze-drying (Roden et. al, 1997b; Šmídková et al., 2010). However, both 
commercial vaccines contain an alum adjuvant, which during freeze-drying extensively 
coagulate into gel-like consistency, the state suspected to inhibit the release of antigen upon 
rehydration (Maa et al., 2006). The loss of efficient immune induction has been reported after 
freezing or freeze-drying of VLPs in aqueous solutions (Shinje et. al, 1991). The use of non-
ionic stabilizers, such as methylcellulose (Corbett et al., 2010) or polysorbate PS80 (Shi et al., 
2005) helps to avoid this effect. Another solution could be the use of another, physically and 
chemically more suitable adjuvant(s), but this strategy would further add to the cost of vaccine 
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and principally could raise safety concerns. This is why convenient dry formulation, meaning 
at least longer shelf life at higher temperatures for marketing purposes is currently missing. 
The examples of the alternative adjuvants to alum are discussed in Section 3. 
Several alternative methods of vaccine needle delivery have been developed. The tattoo 
delivery of DNA has been found as a cost-effective method that may be used in laboratory 
conditions when more rapid and more robust immune responses are required (Pokorná et 
al., 2009). The second method, a novel dry-coated densely packed Macroflux® 
microprojections array skin patch, was established as an alternate delivery system to 
intramuscular injection for delivering an alum adjuvanted vaccine Gardasil (Shi et al., 2005). 
Besides the effort to improve the formulation, storing properties and methods of vaccine 
delivery, the first generation of HPV prophylactic vaccines based on IM delivery of HPV 
antigens of the recombinant VLPs reached its limits with two vaccines produced in 
baculovirus and yeast cell culture on the market. In parallel with development of these 
vaccines there were successful attempts to produce recombinant VLPs also in various plant 
expression systems (see Section 2.4). Plant expression of HPV vaccines pursues several 
objectives as the cost efficiency, production of uncontaminated safe product, scale up and 
potential edible vaccine format. Currently HPV VLPs are readily produced in several plant 
systems with newly developed technologies for industrial large-scale transient production 
that can successfully compete with current production of L1 based VLPs vaccines. 
Nevertheless the cost of clinical trials, of approval and implementation of new technologies 
is so inhibitory high that there will be hardly any HPV vaccine of the first generation 
produced in plants that will reach the market. More realistic expectation is that developed 
plant technologies will compete with established procedures for production of new, 
improved generation of vaccines, when their advantages will surplus currently marketed 
vaccines and expected market success will justify the cost of clinical trials and production. 
2.3 Vaccines of the second generation 
2.3.1 L2 based vaccines 
The limitation of current vaccines is that neutralizing antibodies induced by immune response 
to L1 based VLPs are type-restricted (Wakabayashi et al., 2002). Addition of other HPV types 
VLPs to the existing vaccines would be viable approach only in the case of a small increase in 
the overall cost of the vaccination scheme. In contrast to L1, Pastrana et al. (2005) showed in in 
vitro assays that antigen determinant present on the N’-end of L2 coat protein can induce 
broad range of cross neutralizing antibodies in mouse and rabbit sera. These results raise the 
possibility that a monovalent vaccine could protect against a broad range of genital HPV 
types. Unfortunately, neutralizing antibody titers against the papillomavirus type from which 
the L2 vaccine was derived were generally higher than the titers against heterologous types 
and lower than those induced by L1 VLPs (Pastrana et al., 2005; Roden et al., 2000). This can be 
avoided by construction of concatenated multiple L2 fusion proteins derived from known 
cross-protective epitopes of several divergent HPV types. These fusion proteins, consisting of 
L2 epitopes of 3-22 HPV types, were able to induce high neutralizing antibody titers against all 
heterologous HPVs tested at a level comparable to that induced by L1 VLPs. In addition, L2 
polypeptides have the advantage that they could be produced in E. coli, and therefore 
manufacturing would be easier and cheaper in comparison to production of VLPs. The most 
promising approach of the non-VLPs second generation of HPV vaccines includes L1 
capsomeres and L2 protein (Stanley, 2010). 
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2.3.2 Therapeutical vaccines 
The therapeutic vaccines reduce or eradicate existing disease or infections by targeting cells 
expressing tumor-associated or tumor-specific antigens on their surface (Ma et al., 2010). 
There are many different types of therapeutic vaccine candidates based on viral gene 
peptides and proteins (Xie et al., 2011; Kenter et al., 2008; Melief et al., 2007; Fiander et al., 
2006), DNA (Alvarez-Salas et al.; 2008, Sheets et al., 2003) and various viral and bacterial 
vectors (Brandsma et al, 2009, Davison et al, 2003). They all aim to induce specific cell-
mediated immunity and in most cases the targets are the E6 and E7 proteins. Whereas L1 
and L2 are expressed only in terminally differentiated keratinocytes, E6 and E7 are 
constitutively expressed at all layers of epithelium-infected cells (Fig. 3).  
 
Fig. 3. Cervical stratified squamous epithelial cell architecture and the expression of HPV 
proteins after infection. Daughter cells of epithelial stem cells divide along the basement 
membrane and then mature vertically through the epithelium without further division. 
After introduction of HPV into stem cells in the basal layer of the epithelium, expression of 
viral non-structural proteins E1-E7 occurs. Under the regulation of these proteins, the 
dividing-cell population expands vertically and epithelial cell differentiation is delayed and 
is less complete. Viral proteins are expressed sequentially with differentiation as shown, and 
mature virions are produced only in the most superficial layers of the epithelium. 
Intraepithelial antigen-presenting cells (APCs) are depleted in the HPV-infected epithelium. 
(http://www.ircm.qc.ca/LARECHERCHE/axes/Biologie/Virologie/Pages/Projets.aspx) 
E6 and E7 bind p53 and pRB human tumor suppressor genes (Duensing et al., 2000). These 
oncoproteins are involved in the malignant transformation of HPV-infected cells and are 
thought to be required for continued tumor growth. They are the primary targets of 
therapeutic vaccines, most of which have been designed to treat later stages of the disease. 
The E1 and E2 proteins are necessary for HPV replication within the cell before the virus is 
integrated into the host DNA (Doorbar et al., 1991). Because E1 and E2 are expressed 
already early in the progress of at HPV infection and at higher levels than E6 and E7, they 
may be the best targets for a therapeutic vaccine designed to treat early stages of the disease, 
such as low-grade dysplasia (Carvajal et al., 2007). Many candidate vaccines with 
therapeutic potential are currently tested in ongoing trials; however, there is low expectation 
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that any of the current therapeutic vaccines will have a substantial public health impact in 
the near future (Ma et al., 2010). 
2.4 Vaccine production in plants 
2.4.1 Posttranslational modification of the therapeutic proteins in plants 
Therapeutic recombinant proteins are produced in many hosts from prokaryotes to human 
cells. When the protein of interest is of eukaryotic origin, one of the production objectives 
besides yield, solubility and stability is a posttranslational modifications (PTM) required for 
structural integrity and biological activity of the protein. Microbial expression systems are 
generally used for expression of simple proteins, because, PTM, including signal peptide 
cleavage, propeptide processing, protein folding, disulfide bond formation and 
glycosylation, might not be achieved in prokaryotes. Contrary to prokaryotes, plants are 
capable of PTM as other higher eukaryotes for safe and low cost production biologically 
active proteins (Dieryck et al., 1997; Ma et al., 1995). The correct folding and assembly of 
plant-produced antibody molecules, which requires interactions with several chaperones 
and with processing and glycosylation enzymes, illustrates that most co- and 
posttranslational events are similar in plants and mammals (Table 1). 
Protein glycosylation is assumed as the most important PTM with significant effects on 
protein folding, conformation, distribution, stability and activity. In plant cells, as in other 
eukaryotic cells, N-glycosylation starts during co-translation in ER, when an oligosaccharide 
precursor is added to Asn residues that is constituent of the N-glycosylation-specific 
sequences Asn-X-Ser/Thr. The differences in the maturation of plant and mammalian N-
glycans appear during the late processing in Golgi apparatus, when core alpha(1,6)-linked 
fucose residues and terminal sialic acid are attached in mammals, whereas beta(1,2)-xylose 
and core alpha(1,3)-fucose residues in plants (Fig.4).  
 
Fig. 4. N-glycan structures in human and plant. N-glycosylation patterns processed in plant 
cells differ from those of mammal 
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Posttranslational modification
Location of the reaction in 
animal cell 
Identification in plants and location 
Glycosylation 
O-glycosylation 
Secretory pathway, nucleus   
and cytosol 
Yes. Sugar addition on Hyp, Ser, Thr 
N-glycosylation Secretory pathway Yes. Minor differences in modification 
Glycation Yes 
Proteoglycan Secretory pathway Yes 
Attachment of fatty acids 
S-acylation Cytosol Yes 
N-myristoylation Cytosol Yes 
Prenylation Cytosol Yes 
Glypiation Cytosol Yes 
Cholesterol link Cytosol Not identified. 
Attachment of ions 
Phosphorylation Cytosol, secretory pathway 
Yes. No mannose-6-phosphate in plant 
N-glycans 
Sulfatation Secretory pathway Not identified in secretory pathway 
Gamma-carboxylation ER Not identified. 
Proteolysis 
Cleavage of signal peptide ER Yes. ER 
Cleavage of propeptide ER/Golgi Yes. ER, Golgi, vacuole 
Other posttranslational  modifications 
Hydroxylation ER Yes. ER, Golgi 
Cross-linking modifications ER Yes. ER, cytosol 
Acetylation Secretory pathway and cytosol
Yes. Function not yet understood in 
plants 
Oligomerization ER Yes. ER 
Selenoprotein Cytosol 
Not identified in higher plants, 
described in C. reinhardtii 
Deamidation Intra- and extracellular Yes 
Oxidation Intra- and extracellular Yes 
Table 1. Protein modifications in plant and animal cells. (Gomord & Faye, 2004, modified) 
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Plant specific residues were described to be constituents of the glycol-epitopes of some plant 
allergens, showing IgE binding and causing mediator release by human basofils (van Ree et 
al., 2000). Moreover, the injection of a plant glycoproteins or plant-made antibodies 
containing plant-specific N-glycans was found to elicit production of antibodies specific for 
beta(1,2)-xylose and alpha(1,3)-fucose-containing glyco-epitopes in most laboratory 
mammals and non-allergic human blood donors. Their presence may induce a rapid 
immune clearance of plant-glycosylated therapeutics from the blood steam (Bardor et al., 
2003). One strategy to prevent the addition of immunogenic glycans is to store therapeutic 
proteins carrying KDEL signal within ER (Ko et al., 2003). Second strategy is based on the 
inhibition of Golgi glycosyltransferases of plants. The moss Physcomitrella patens is the only 
known plant with high frequency of homologous recombination, thus allowing relatively 
easy knockouting of target genes. The knockout of alpha(1,3)-fucosyltransferase and 
beta(1,2)-xylosyltransferase genes in the moss Physcomitrella patens prevents the production 
of plant-specific glyco-epitopes without effecting the secretion of the protein (Koprivova et 
al., 2004). Third attractive strategy to “humanize” plant N-glycans is expressing of 
mammalian glycosyltransferases in plants. Like N-glycosylation, O-glycosylation is 
important for protein function. Surprisingly, little attention is paid so far to O-glycosylation 
status of plant produced therapeutic proteins. 
2.4.2 L1 based prophylactic vaccines and the yields of L1 produced in different plant 
systems 
L1 when expressed in plants readily assemble into VLPs indistinguishable in size from 
baculovirus expressed VLPs in insect cells (Fig. 5). Sucrose sedimentation analysis also 
showed that there is a large amount of not, or only partially assembled molecules, 
presumably capsomeres (fractions 18–24), as well as other larger aggregates (fractions 1–8) 
when compared to the insect cell-produced protein (Maclean et al., 2007). L1VLPs can be 
produced either in transgenic plants stably transformed with an expression cassette or 
transiently using one of several available plant-virus derived expression systems. Initially 
published yields of L1 expression was low, in a range of 1% of the total soluble protein, 
which is far lower than industrial demand of more than 5% (Rybicky, 2010). For example, 
Warzecha et al. (2003) obtained approximately 20 ng HPV-11 L1 per g in transgenic potato 
tubers; Varsani et al., 2003b, 2006 obtained 4 ng HPV-16 L1 per g of leaf tissue in 
transgenic tobacco and approximately 40 ng per g of Nicotiana benthamiana leaves 
transiently transformed with a tobacco mosaic virus vector and Kohl et al. (2006) and Liu 
et al. (2005) achieved approximate yield of L1 at the range 0.05% TSP in transgenic 
tobacco. 
Nevertheless, during passed years, necessary steps to improve L1 gene expression were 
recognized and applied. Firstly it was removal of the carboxy-terminal nuclear 
localization signal sequence (NLS) of L1 that has been shown to enhance expression in 
transgenic plants. Moreover, the results indicated that full-length L1 is localized 
essentially entirely within the nucleus (Fig. 6A), whereas cells that express truncated form 
of L1 in a diffuse pattern within entire cell (Fig. 6B.) (Warzecha et al., 2003). Transient 
expression of full-length L1 protein in cytoplasm of tobacco leaf cells after agroinfection 
was described by Šmídková et al. (2010) (Fig. 6C).  
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Fig. 5. Sedimentation analysis of transiently expressed HPV-16 L1 protein isolated from 
Nicotiana benthamiana plants (left panel) and insect cells (right panel) in sucrose gradient. 
The concentration of L1 in fractions was estimated by capture ELISA (closed circles); open 
squares – ELISA analysis of control, no expressing plants; open circles and right axis - 
refractive index. Fraction 1 corresponds to the bottom of the centrifuge tube (Maclean et al., 
2007). 
 
Fig. 6. Expression of HPV L1 proteins in tobacco cells. Transgenic tobacco expressing either 
full-length (A) or truncated (B) L1 coding sequence fused in frame at the carboxy terminus 
of GFP. Fluorescence appears as bright areas (Warzecha et al., 2003) (C) Localization of L1 in 
cryosections of Nicotiana benthamiana leaves agroinfected with plant TRV viral vector 
expressing optimized L1h gene (pTVL1h). The protein was detected by immunofluorescence 
microscopy at 400X magnification. Nuclei were counterstained with DAPI (Šmídková et al., 
2010). 
Biemelt et al. (2003) after failure to express L1 in transgenic potatos, changed amino-acid 
codon usage of L1 gene to that of potato (L1p) and of canonic human cells (L1h). Despite the 
presence of codons rarely used by plant cells and for plant genes atypical high GC content, 
expression of L1h led to high accumulation of L1 protein in transgenic plants, even higher 
than expression of L1p. The effect of increased GC content on expression efficiency of L1 in 
plants has been confirmed by several groups (Maclean et al., 2007; Šmídková et al., 2010), 
nevertheless the published yields of L1 differ significantly one from each other, depending 
on the plant expression system used. For example the change of tobacco cultivar used for 
transgenic expression from Nicotiana tabacum cv. Xanthi to cv. SR1 allowed a 100-fold 
increase in expression of the native L1 from viral isolate (Rybicky, 2010). The transient 
expression of the same L1 using TMV plant viral expression vector resulted in further, one 
order of magnitude, increase of L1 over the expression in transgenic tobacco (Varsani et al., 
2006). A strategy of optimization procedure for L1 transient expression described recently 
Šmídková et al. (2010). The results are summarized on Fig. 7, depicting A) The course of L1 
expression from original virus isolate sequence (41% GC) and L1p sequences optimized for 
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Solanace plants expression (39% GC) and from canonic human cell optimized sequence L1h 
(61% GC); B) In three plants: tomato and Nicotiana benhamiana and Nicotiana tabacum 
tobaccos; C) In two plant viral expression vectors: PVX and TRV and by D) Two 
transformation methods: agroinfection (method in which a virus infects a host as a part of T-
DNA of Ti plasmid carried by Agrobacterium tumefaciens) and Agrobacterium mediated 
transfer of expression cassette into cells after infiltration of leaves. The optimization of L1h 
transient expressed from pTRV vector after Agrobacterium infiltration of tomato host plants 
yielded 45 mg of VLPs per kilo of fresh leaves, the yield that is close to industrial acceptable 
level. 
 
 
Fig. 7. Time course of the L1 transient expression. (A) Expression of original native HPV L1 
gene sequence L1ori and sequences optimized for expression either in plants L1p or in 
mammalian cells L1h from plant TRV-based vector pTV00; (B) Expression of L1h from 
pTV00 vector in leaves of Nicotiana benthamiana, Nicotiana tabacum and Solanum lycopersicum 
L. (tomato); (C) Comparison of the expression of L1h gene from plant tobamo virus (TRV) 
based expression vector pTV00 and from potato virus X (PVX) based vector pGR106; (D) 
The yield of L1protein reached by viral agroinfection or by Agrobacterium mediated transfer 
of expression cassette into leaf cells of Nicotiana bentamiana (Šmídková et al., 2010). 
Nevertheless the highest yield (3 g/ kg fresh leaves; 24% TSP) of plant-produced L1 ever 
was achieved by Fernández-San Millán et al. (2008) when expressing unmodified L1 
sequence of primary HPV16 virus isolate from expression cassette stably integrated in 
tobacco chloroplasts genome. Expression in plant chloroplasts is an emerging system when 
compared to nuclear transformation. Plastid genome engineering offers many advantages 
over nuclear genome, including targeted recombination based integration, high levels of 
transgene expression due to high copy number, absence of epigenetic effects, transgene 
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containment via maternal inheritance and multi-gene expression in a single transformation 
event (Chebolu and Daniell, 2009). Recently the expressions of transgenes in plastids as high 
as 70% and 72% of total leaf protein was reported by Oey et al. (2009) and Ruhlman et al. 
(2010), respectively. 
Results of L1 expression in various plant systems up to date are summarized in Table2. 
  
Antigen Production system and yield Efficacy data 
HPV-16 L1 
Agrobacterium-transformed Nicotiana 
tabacum cv. Xanthi plants 
Assembled in VLPs 
4 μg/kg ww 
Weakly immunogenic in rabbit 
HPV-11 L1 
Transgenic potato tubers 
Assembled in VLPs 
20 μg/kg 
Weakly immunogenic in orally 
vaccinated mice 
HPV-16 L1 
Transgenic potato tubers 
Assembled in VLPs 
12 mg/kg 
Weakly immunogenic in orally 
vaccinated mice 
HPV-16 L1 
Transgenic tobacco plants 
Assembled in VLPs 
20 mg/kg ww 
Highly immunogenic in mice 
injected with purified product 
HPV-16 L1 
Protein expressed in Nicotiana 
benthamiana by TMV-derived vector 
40 μg/kg wet leaves 
ND 
HPV-11 L1 
Transgenic N. tabacum 2 mg/kg ww 
Transgenic Arabidopsis thaliana 12 
mg/kg ww 
N. benthamiana via rTMV 10 mg/kg ww
ND 
HPV-16 L1 
Agroinfiltrated N. benthamiana, human 
codon usage-optimized gene; protein 
targeted to chloroplasts, assembled in 
VLPs 
500 mg/kg ww 
Antibodies elicited in mice by 
injection of crudely purified 
extracts neutralized HPV-16 
pseudovirion transfection of 
HEK293TT cells 
HPV-16 L1-
Rubisco/ 
ATPase peptide 
fusion 
Protein produced in chloroplasts of 
transplantomic tobacco plants from 
native or chloroplast-optimized genes
60 mg/kg ww 
ND 
HPV-16 L1 
Protein produced from unmodified 
genes in chloroplasts of transplantomic 
tobacco plants 3 g/kg ww 
Mice injected intraperitoneally 
with partially purified VLPs with 
Freund’s or aluminium hydroxide 
adjuvants produced neutralizing 
antibodies 
Table 2. Plant-derived HPV antigens for the development of prophylactic vaccines. HPV: 
Human papillomavirus; ND: No data; PVA: Potato virus A; PVX: Potato virus X; rTMV: 
Recombinant tobacco mosaic virus; TMV: Tobacco mosaic virus; VLP: Virus-like particle; 
ww: Wet weight. (Giorgi et al., 2010) 
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2.4.3 The structure and stability of plant derived L1 
The assembly of VLPs in plants after transient (Fig. 8 A, C) or stable (Fig. 8D) L1 expression 
was confirmed by electron microscopy of leaf crude extracts.  
 
Fig. 8. Electron microscope images of uranyl acetate negatively stained HPV VLPs expressed 
in various systems: (A) Extracts prepared from freeze-dried leaves of Nicotiana benthamiana 
transiently expressing L1. V - HPV16L1 55-nm VLPs particles, C - HPV16 L1 capsomeres, T - 
flexible rods of plant TRV virus (Šmídková et al., 2010); (B) CsCl-purified baculovirus 
expressed VLPs in insect cells; (C) Crude extracts from top leaves of Nicotiana benthamiana 
expressing HPV VLPs from plant TMV virus. Two rods of TMV are shown together with 
VLPs (Varsani et al., 2006); (D) CsCl-purified VLPs from transgenic potato plants. VLPs have 
band density 1.32g/ml (Biemelt et al., 2003). 
The structure of VLPs is not stable upon freezing and thawing, but plant expressed VLPs 
retain their structure during freeze-drying in both, the plant extracts and the plant tissue 
Fig. 8 and 9 (Maclean et al, 2007). 
 
Fig. 9. Stability of L1 VLPs transiently expressed from pTV00 vector in Nicotiana benthamiana 
leaves: (A) after freezing and thawing extract from fresh leaves. Approximately 50% of VLPs 
loses 3D structure when extract is stored at -20°C or –70°C, respectively; (B) Upon freeze-
drying of leaves and extraction cycle. More than 90 % of L1 retains conformation in extracts 
from freeze-dried leaves (third column) in comparison to extract prepared from fresh leaves 
(first column). Controls are extracts from leaves prepared the same way, but from plants 
inoculated with an empty pTV00 vector.  
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 160 
2.4.4 Immunogenicity of plant derived L1 
The first report on production of HPV VLPs in plants and testing of their immunogenicity 
appeared in literature in 2003. Varsani et al. (2003b) was the first to express full-length 
native HPV-16 L1 gene in transgenic Nicotiana tabacum cv. Xanthi. This plant-produced 
protein assembled into recognizable VLPs and was immunogenic, when injected into rabbits 
with Freund’s incomplete adjuvant. Since then, several groups has observed induction of 
specific antibodies after subcutaneous injection of either purified plant-derived HPV16 L1 
VLPs (Biemelt et al., 2003) or of the crude extract from the tobacco leaves expressing HPV16 
L1 protein (Fig. 11A) (Maclean et al., 2007; Šmídková et al., 2010). Despite the fact that in 
plant extracts majority of expressed L1 protein was present as capsomeres besides VLPs Fig. 
8A, the extracts were highly immunogenic without any additional adjuvant (Maclean et al., 
2007, Šmídková et al., 2010). The antibodies induced by immunization with plant extract 
depicted on Fig. 8A preferentially recognized fully assembled L1 VLPs (Fig. 12A) and 
neutralized in vitro HPV16 virions (Fig. 12B). Plant expressed L1 in crude extract also 
induces CTL (Fig. 11B). 
These findings suggests that principal antigenic determinant is either entire VLP or 3D 
structure specific for fully assembled VLPs and these antigens are present in crude 
extracts from plants transiently expressing L1 in enough quantity to elicit immune 
response equal or higher than purified VLPs from insect cells. Moreover immunization 
with plant L1 crude extracts induce cellular responses characteristic for active vaccine 
(Šmídková et al., 2010). 
Mucosal delivery has several advantages over needle administration. Immune response is 
best achieved by direct application of a vaccine to mucosal surfaces and in addition mucosal 
application of a vaccine can also induce humoral, cell-mediated and systemic immune 
responses (Rigano & Walmsley, 2005). HPV VLPs are immunogenic when administered 
orally and stable in the environment of the gastrointestinal tract. Rose et al (1999) and 
Gerber et al. (2001) reported that as little as 1-10 micrograms are sufficient to induce high 
titers of L1 specific antibodies after oral application when administered with LT or CpG 
DNA adjuvants. Besides VLPs also capsomeres (L1-pentamers) and T=1 particles (12 L1-
pentamers) depicted on Fig. 10 were investigated for oral immunogenicity in mice. Mutated 
L1 gene (L1_2xCysM) with two cysteines replaced by serines was used to generate 
capsomeres and T=1 particles. Compared to capsomeres, VLPs induced higher titers of 
neutralizing and IgA secreted antibodies, while cytotoxic T cell responses was comparable. 
The induction of secreted IgA antibodies was observed after oral but not after subcutaneous 
immunization (Thönes & Müller, 2007). 
The concept of using tissue of plants expressing vaccine antigens as an edible vaccines 
attracted already a lot of attention and is still of special interest. A number of clinical studies 
demonstrated the induction of specific antibodies after oral immunization using crude plant 
material containing, for example, hepatitis B or Norwalk virus antigens (Lal et al., 2007). 
Likewise, oral immunization using crude potato tubers expressing L1 protein can induce 
specific antibody (Warzecha et al., 2003, Biemelt et al., 2003). Moreover, HPV L1-E6/E7 
based chimeric VLPs have been successfully expressed in tomato fruits, which were able to 
elicit humoral and cytotoxic T-cell activity in mice (Paz De la Rosa et al., 2009). 
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Fig. 10. Analysis of different L1 assembly forms by electron microscopy. Capsomeres (L1-
pentamers), T1-particles (12 L1-pentamers) and VLPs (T7 particles of 71 L1-pentamers) 
purified from infected insect cells expressing the wild-type HPV 16 L1 gene (L1wt) or 
mutated L1 (L1_2xCysM) were analyzed by electron microscopy after uranyl acetate 
negative staining (Thönes & Müller, 2007). 
 
 
 
 
 
 
 
Fig. 11. Antibody (A) and cytotoxic T-lymphocytes (B) induction by L1-VPLs. Response 
elicited by control plant extracts (mice 1 - 5), control plant extract from Nicotiana benthamiana 
containing purified VLPs from insect cells (mice 6 - 10) and crude plant extracts from leaves 
expressing L1 (mice 11 - 25) in C57BL/6 mice. Collected sera from individual mice were 
tested by ELISA for induction of specific antibody (y-axis in OD 450 units). CTLs induction 
was measured by ELISPOT analysis of splenocytes recovered from scarified animals. The 
number of CTLs spots was recorded by an ELISPOT reader and expressed as a mean per 106 
splenocytes 
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Fig. 12. (A) The specificity of mAb E2 toward various L1 assembly structures. VLPs, T1-
particles (12 L1-pentamers) and capsomeres produced in insect cells were absorbed on the 
microtiter plates and analyzed by ELISA. Interactions of hybridoma E2 supernatant is 
compared to antibodies obtained after immunization with insect cell-derived VLPs (1.3.5.15, 
E10 and 25C). (B) Neutralization assay. Sera of mice and of E2 hybridoma supernatant were 
tested for neutralization of infection of 293T cells by HPV pseudovirions (Psv). Percent of 
neutralization obtained by incubation with mice sera diluted 1:50 and that of E2 hybridoma 
supernatant diluted 1:5, 1:20, 1:100, 1:500. Neutralization activity of mice sera was compared 
to a high titer rabbit polyclonal anti-L1 antiserum 4543 (100 %) and to the mAb’s 1.3.1 and 
1.3.2 as additional positive controls. 
2.4.5 Plant based therapeutic and second-generation vaccines 
Capsomeres can be used as a potential cost-saving substitute of VLPs, as L1-pentameric 
capsomeres are considered thermo-stable, the advantageous feature for the use in 
developing countries where cold chain administration and delivery of vaccine is difficult to 
maintain (Stanley et al., 2008). A promising step towards a capsomeres-based vaccine was 
described by Yuan et al. (2001) when dogs were completely protected against canine oral 
papillomavirus (COPV) infection by capsomeres vaccination. Capsomeres have been also 
reported to induce neutralizing antibodies and L1-specific cytotoxic T-lymphocytes (CTLs) 
upon oral, intranasal and subcutaneous immunization (Dell et al., 2006; Thönes & Müller, 
2007; Schadlich et al., 2009). To increase immunogenicity, L1_2xCys mutant version of 
HPV16 L1 protein was fused with LTB as an adjuvant and expressed in chloroplasts 
(Waheed et al, 2011a, 2011b). 
Plant expressed HPV antigens to be used as therapeutic vaccine to date are summarized in 
Table 3: 
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Antigen Production system and yield Efficacy data 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7 
3–4 μg/g fresh leaves 
40% of mice immunized with E7- 
containing crude leaf extract were 
protected from growth of cancer 
induced by E7-expressing C3 cells 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7; protein 
targeted to secretory pathway 
15–20 μg/g fresh leaves 
80% of mice immunized with E7-
containing crude leaf extract were 
protected from growth of cancer 
induced by E7-expressing C3 cells 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7; protein 
targeted to secretory pathway 
Mice vaccinated orally with freeze-
dried E7-containing leaf extract mixed 
with feed produced high titer of anti-E7 
antibodies 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7 
Dendritic cells pulsed with E7-
containing leaf extract were able to 
prime naive lymphocytes to induce E7-
specific CTLs 
LicKM–E7GGG 
N. benthamiana tobacco leaves 
infected with LicKM–E7GGG, using 
a launch vector expression system 
400 μg purified protein per gram of 
fresh leaves 
Purified protein injected into mice 
induced IgG and CTL response and 
protected them against challenge with 
E7-expressing tumor cells in both 
prophylactic and therapeutic 
vaccination regimen 
11-kDa Zera zein-derived 
peptide–E7 mut 
N. benthamiana via agroinfiltration 
Mice vaccinated with the protein were 
protected against tumor cells 
expressing E7 
PVX CP–HPV-16 E7GGG DNA vaccine 
DNA vaccine was able to protect 
vaccinated mice from the growth of 
tumors induced by E7-expressing TC-1 
cells 
PVX CP–HPV-16 E7 Tobacco chloroplast ND
SAP-KQ–E7GGG 
a) DNA vaccine 
b) Expressed in N. benthamiana 
a) DNA vaccine tested in therapeutic 
setting was able to block tumor growth 
in the 40% of challenged mice 
b) Not performed 
HPV-16 L2–PVA CP–E7 
epitope fused protein 
Expressed by PVX in Nicotiana 
tabacum, N. benthamiana using 
Agrobacterium tumefaciens-
mediated inoculation 
ND 
HPV-16 VLPs carrying L1 
fused to a string of 
epitopes from E6 and E7
Tomato seedling cotyledons HPV-16 
VLPs carrying L1 fused to string of 
epitopes from E6 and E7 using A. 
tumefaciens-mediated inoculation
Mice injected with chimeric VLPs were 
able to develop neutralizing antibodies 
and specific CTLs 
Table 3. Plant-derived HPV antigens for the development of therapeutic vaccines. CP: Coat 
protein; CTL: Cytotoxic T lymphocyte; HPV: Human papillomavirus; ND: No data; PVA: 
Potato virus A; PVX: Potato virus X; SAP-KQ: Mutagenized type I ribosome inhibiting 
proteins from Saponaria officinalis; VLP: Virus-like particle. (Giorgi et al., 2010) 
The important proof of the L2 plant-produced nonhuman papillomavirus vaccine efficiency 
was published in connection with the purified rTMV particles displaying cottontail rabbit 
papillomavirus (CRPV) or rabbit oral papillomavirus (ROPV) L2 protein peptides on their 
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surface (Palmer et al., 2006). This pseudovirion system was also used to express entire native 
L1 gene of CRPV. Intramuscular injection with of CRPV L1-containing concentrated plant 
extract derived from transgenic tobacco protected rabbits against CRPV challenge (Kohl et 
al., 2006).   
Since VLPs based vaccines are not effective in the therapy of diseases, an important goal is 
development of anti-HPV vaccines with either therapeutic or both prophylactic and 
therapeutic properties. Few studies were performed with viral oncoproteins expressed in 
plants. HPV-16 E7 was transiently expressed using a viral vector based on potato virus X 
(PVX) in the Nicotiana benthamiana, Nicotiana rustica, Nicotiana tabacum, Chenopodium quinoa 
and the tomato Solanum lycopersicum L. cv. Micro-Tom. The highest expression of HPV-16 E7 
3–4 μg/g of fresh leaves was achieved in Nicotiana benthamiana and the expressed E7 
induced specific humoral and cell-mediated immune responses in mice (Franconi et al., 
2002, 2006). The efficiency of chimeric constructs when E7 is fused to other proteins and 
expressed in plants was also reported. The expression of HPV-16 E7 fused with the PVX CP 
in tobacco chloroplasts has been recently reported. The expression of the fusion protein in 
this system was higher than E7 alone (Morgenfeld et al., 2009). Mutated E7, E7GGG, which 
lacks the retinoblastoma binding site, and thus the native transformation potential, was 
fused to the Clostridium thermocellum b-1,3–1,4-glucanase (LicKM) as a carrier molecule for 
expression in plants. The expression of fusion protein in Nicotiana benthamiana yielded 400 
μg of purified protein per gram of leaf (Musiychuk et al., 2007). Injection of the purified 
LicKM–E7GGG fusion protein into mice induced both E7-specific IgG and cytotoxic T-cell 
responses, and protected mice against challenge with E7-expressing tumor cells (Massa et 
al., 2007). The successful expression of chimeric HPV-16 L1 protein fused to a string of three 
E7 and one E6 epitopes in transgenic tomatoes demonstrates that a combination 
prophylactic ⁄ therapeutic HPV vaccine could be produced in plants (Paz de la Rosa et al., 
2009; Monroy-García et. al, 2011). Unfortunately, while the produced VLPs stimulated both 
antibody and T-cell responses, yields were low in the range 0.05 – 0.1% of total soluble 
protein. Similarly, combined vaccine based on minor capsid protein L2 and an epitope of E7 
oncoprotein was successfully expressed in plants, when an epitope of the L2 protein and an 
epitope of E7 oncoprotein were fused to the N’- and C’-end of PVA CP, respectively. The 
construct was cloned into a PVX-based vector and transiently expressed in plants using 
Agrobacterium-mediated inoculation (Čeřovská et al., 2008). 
3. Vaccine formulation 
3.1 Parenteral administration  
3.1.1 Adjuvants 
The goal of vaccination is to generate a strong immune response to the administered 
antigen. Papillomavirus VLPs themselves are good “inducers” of immune response and 
antigen determinants present on their surface are able to activate dendritic cells (DCs) for 
triggering T-cell activation (Bontkes et al., 2005; Yang et al., 2005). Nevertheless, for efficient 
clinical use additional adjuvants are needed not only to enhance the immune response, but 
also assuring achievement of appropriate type of protective immunity in each situation.  
The aluminum (alum) salts or gel-based adjuvant formulations used e.g. in HPV Gardasil 
vaccine are currently approved in vaccines licensed for human use in the US. Nevertheless a 
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significant number of compounds tested for adjuvant effect are clearly more effective than 
alum, albeit usually accompanied with a higher toxicity as e.g. Freund’s complete adjuvant. 
This is the main reason preventing their use as adjuvants in human vaccine formulations. As 
adjuvants were successfully tested low toxic mutants of the cholera toxin (CT) (Yamamoto et 
al., 1997) and E.coli heat-labile enterotoxin (LT) (Chong et al., 1998). The inactive B-subunits 
of these toxins proved to be a strong mucosal (oral, nasal, vaginal, etc.) adjuvants (e.g. 
Salmonella toxin B subunit is used in commercial Cervarix vaccine) for a wide variety of 
antigens in mice and other animal species so far tested, however their use in humans is 
limited (Chong et al., 1998). This is why there is a growing interest to develop new 
adjuvants eliciting high mucosal, humoral and cellular immune response accompanied by 
negligible or low toxicity. 
Antigen delivery systems Immunopotentiators 
Insoluble aluminum compounds MPL and synthetic derivates 
Calcium phosphate MDP and derivatives 
Liposomes Oligonucleotides (CpG, etc.) 
Virosomes™ Double-stranded RNA (dsRNA) 
ISCOMS® 
Alternative pathogen-associated 
Molecular patterns (PAMPs) (E. coli heat 
Labile enterotoxin (LTB); flagellin) 
Microparticles (e.g., PLG) Saponins (Quils, QS-21) 
Emulsions (e.g., MF59, Montanides) 
Small-molecule immune potentiators  ( SMIPs) 
(e.g., resiquimod [R848]) 
Virus-like particles & viral vectors Cytokines & chemokines 
Table 4. Examples of adjuvant classes (O'Hagan & Rappuoli, 2004) 
3.1.2 Adjuvant effect of plant extracts 
Plant extracts are known to contain various compounds, which supposedly have 
immunostimulatory and immunosuppressive effects (Wagner & Proksh, 1985). Plant crude 
extracts and their components were tested for their adjuvant capacity. The extract from 
leaves of Nicotiana bethamiana co-administrated subcutaneously with HPV16E7 (Franconi et 
al., 2002) or HPV16L1 VLP´s (Maclean et. al, 2007; Šmídková et al., 2010) enhanced specific 
humoral and cellular immune response in tested mice. Freund’s adjuvant added to the plant 
extract did not increased noticeably humoral response elicited by HPV16L1 VLP´s in 
subcutaneously immunized mice and results indicate that the addition of Freund’s adjuvant 
to plant extract might be even deleterious (Maclean et. al, 2007). The study of Isfar et al. 
(2004) compares adjuvant effect of CT and of aqueous extract of Solanum torvum (STE). STE 
was shown to evoke an increase in IgA titer comparable to that of CT when co-
administrated with ovalbumin intraperitoneally. No acute toxic effects were evident with 
the used dose range. Plant extract has been shown to induce DC maturation of dendritic 
cells. This effect was not caused by lipopolysaccharide (LPS) but rather by presence of heat-
resistant products mimicking the effect of LPS in foliar extract (Di Bonito et al, 2009).  
Probably the most studied plant compound with adjuvant effect is the saponin fractions 
isolated from Quillaja  saponaria (Newman et al., 1992). The mechanism of saponin effect is 
complex and, apart from direct cellular stimulation, there is also evidence that saponins may 
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enhance oral immunization by protection of antigen from degradation by digestive enzymes 
and by increasing permeability of the intestine to macromolecules (Campbell, 1995).  
All these findings are promising for development of needle-free administration route of 
immunization as an alternative to intramuscular vaccine application. For this purposes 
intranasal, intravaginal, transdermal, sublingual and intramuscular administration routes 
were tested for systemic immune responses against HPV16L1 using (Cho et al., 2010). The 
sublingual route provided the most effective mucosal secretory IgA (sIgA) and serum IgG 
responses, cholera toxin subunit B (CTB) showed the most promising adjuvant activity. 
3.2 HPV L1 antigens as an edible vaccine? 
The majority of currently licensed vaccines are administered parenterally, even though they 
have the disadvantages of patient reluctance to tolerate needle sticks and lack of mucosal 
immune induction (Velasquez et al 2010). Edible vaccine represents further approach to self-
administrated nonparenteral vaccine that could solve the problem of high cost and need for 
appropriate storage of currently available preventive HPV vaccines. 
Thönes & Müller (2007) investigated the oral immunogenicity of different assembly forms of 
HPV 16 L1: T7-VLPs, T1 particles and capsomeres produced from Baculovirus expression 
vector in insect cells and showed that all three assembly forms induce humoral and cellular 
immune responses after oral vaccination of mice. The anti-L1 antibodies were conformation-
specific and showed neutralizing activity in a pseudovirion-based assay. They also 
investigated whether adjuvants have an effect on oral immunogenicity when co-
administrated with different L1 forms. Besides saponins, which were significantly toxic if 
applied orally, co-administration of either CpG DNA or Escherichia coli heat-labile 
enterotoxin LT(R192G) had no apparent enhancing effect on the production of anti-L1 
antibodies. Compared to capsomeres, VLPs induced stronger humoral immune responses 
while the CTL responses were induced at comparable levels.  
To establish an edible HPV16 vaccine Sasagawa et al., (2005) constructed a recombinant 
HPV16 L1-expressing Schizosaccharomyces pombe yeast strain to be administrated as freeze-
dried yeast powder orally as an edible vaccine, with or without the mucosal adjuvant heat-
labile toxin LT (R192G), to mice. After the third immunization, none of the mice that 
received the edible HPV16 vaccine showed specific antibody responses, whereas all of the 
positive controls that were administered intranasally with 5 μg of HPV16-virus-like particles 
(VLP) had serum IgG, and genital IgA and IgG that reacted with HPV16-VLP in enzyme-
linked immunosorbent assays (ELISAs).  
HPV L1 antigens that proof to be highly immunogenic when administrated parenterally 
induce only mild or none response when administrated orally. In light of these experiments 
it seems unlikely that current design of L1 based HPV vaccines will reach the market as an 
edible replacement of existing vaccines. More research is needed to establish vaccine 
concentration and formulation to boost its effect. It is also obvious that the highly phrased 
concept of edible vaccine administrated as plants or fruits for direct consumption in the less 
developed countries is rather romantic dream than reality and have to be corrected. It is 
now clear that if there will be an edible vaccine, it will have complex formulation that will 
be strictly controlled. 
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A good nonparenteral alternative for vaccine delivery could be nasal immunization, which 
already proved to be effective in tests with animals. The obstacles imposed by the normal 
process of mucociliary clearance limiting residence time of applied antigens could be 
circumvent by presence of an inert in situ gelling polysaccharide (GelSite) extracted from 
Aloe vera for nasal delivery of NV VLP antigen (Hefferon, 2010). The nasal cavity is a 
promising site for vaccine delivery because it is easy to access, is highly vascularized, has a 
relatively large surface area, has low proteolytic activity, and is able to induce systemic 
immunity as well as both local and distal mucosal immunity via the Common Mucosal 
Immune System (CMIS)  
4. Conclusions 
The major reason for the vaccine production in plants is that the vaccine antigen production 
is safe and could be potentially cheap and both transient and transgenic productions are 
scalable. Biologically active proteins can be produced more easily in plants than in other 
eukaryotic systems; and that the use of food plants could eventually allow edible and/or 
oral vaccines to be produced cheaper. The recent reports indicate very high yields of human 
vaccine candidates to be obtained via plastid transformation or large scale transient 
expression what could enable to meet the expected requirement of antigen for oral route as 
is required parenterally for the same immune response. A recent review on human trials of 
plant-based oral vaccines summarizing human studies of oral transgenic plant derived 
vaccines against enterotoxigenic E. coli infection, norovirus and HBV adds weight to the 
growing body of evidence that plant-made oral vaccines to these viruses are not only 
feasible, but could effective (Rybicki, 2010). Nevertheless there is still long way to go from 
improvement of antigen yields, to formulation of the vaccine including auxiliary factors 
improving efficacy and stability, to translation of the proposed vaccines into clinical trials 
and, not least, governmental and/or regulatory body approvals. 
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